Hereditary Cancer Program
We provide a risk assessment for individuals whose personal or family history may suggest an inherited predisposition to certain cancers. Those found to be at increased risk due to an inherited gene change can take steps to reduce their chances of developing cancer.
If you are being seen due to a family member's diagnosis or genetic test report, please try to fax a copy of their testing or diagnosis in advance, or bring the genetic testing with you to your visit.
Learn more...About Hereditary Cancer Program
A hereditary cancer evaluation includes a detailed assessment of family history and medical records to determine the cancer risk for the patient and family. If an inherited risk is identified, genetic testing is discussed, including the benefits and limitations, costs and insurance coverage.
For those who choose to pursue testing, results are discussed in detail. Those who carry a predisposing gene change, will be counseled on risk reduction strategies, management options, and testing alternatives for family members.
People who may benefit include people with:
- A "strong" family history of cancer—such as two or more close relatives on the same side of the family diagnosed with the same or related cancers, especially the cancer occurred at an early age (under 50 years old)
- Multiple family members with cancer or multiple related cancers in the same patient, such as bilateral breast, or breast and ovarian cancers
- Unusual cancers or sites of cancers, such as male breast cancer
- Known hereditary cancer syndrome and/or a previously identified cancer susceptibility gene mutation
- Ashkenazi Jewish ancestry
- Anxiety about his or her cancer risk based on personal and/or family history
Accepting new patients
Accepting new patients
Conditions and Treatments:
Hereditary breast and ovarian cancer, Lynch syndrome, familial adenomatous polyposis, hereditary cancer predisposition, Li-Fraumeni syndrome, Cowden syndrome, Peutz-Jeghers syndrome, multiple endocrine neoplasia Type 1 (MEN1), multiple endocrine neoplasia Type 2 (MEN2), Birt-Hogg-Dubé syndrome, Von Hippel-Lindau disease
